Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07365735 · ClinicalTrials.gov registry record · NA

TearCare MGX™ System With and Without Warming Hold

A NA study, sponsored by Sight Sciences.

Completed
Registry status
NA
Development phase
21
Enrollment target

NCT07365735 is a NA study that has completed, run by Sight Sciences. The registered enrollment target is 21 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07365735, a NA study, has completed, sponsored by Sight Sciences.

COMPLETED
Registry status
NA
Development phase
21 participants
Enrollment target

Study Summary

TearCare is an office-based thermal therapeutic eyelid technology cleared by the US Food and Drug Administration for the treatment of evaporative dry eye disease due to meibomian gland dysfunction. In this randomized study, TearCare procedures using the TearCare MGX System (study device) with the extended Warming hold feature will be compared with TearCare procedures using the TearCare MGX System without the Warming hold (control group).

Interventions

  • DEVICE localized heat therapy

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2026-03-17
Est. Completion 2026-05-19
Phase NA

Sponsor

Sight Sciences

14 total trials

What the Registry Record Tells You About NCT07365735

The ClinicalTrials.gov registry entry for NCT07365735 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sight Sciences, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which localized heat therapy is the first listed.

NCT07365735 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT07365735 about?

NCT07365735 is a clinical study titled "TearCare MGX™ System With and Without Warming Hold". TearCare is an office-based thermal therapeutic eyelid technology cleared by the US Food and Drug Administration for the treatment of evaporative dry eye disease due to meibomian gland dysfunction. In this randomized study, TearCare procedures using the TearCare MGX System (study device) with the ex...

What is the current status of trial NCT07365735?

This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2026-03-17. Estimated completion is 2026-05-19.

What interventions are being tested in trial NCT07365735?

The interventions under investigation include: localized heat therapy (DEVICE).

Who is sponsoring clinical trial NCT07365735?

This trial is sponsored by Sight Sciences, which has 14 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.